Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer
Standard
Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. / Eichenauer, Till; Simmendinger, Luca; Kluth, Martina; Chirico, Victoria; Luebke, Andreas M; Höflmayer, Doris; Hinsch, Andrea; Jacobsen, Frank; Hube-Magg, Claudia; Möller-Koop, Christina; Dahlem, Roland; Fisch, Margit; Rink, Michael; Riechardt, Silke; Tsourlakis, Maria Christina; Büscheck, Franziska; Bernreuther, Christian; Clauditz, Till; Lebok, Patrick; Simon, Ronald; Sauter, Guido; Wilczak, Waldemar; Fraune, Christoph.
in: UROL ONCOL-SEMIN ORI, Jahrgang 38, Nr. 6, 06.2020, S. 605.e1-605.e8.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer
AU - Eichenauer, Till
AU - Simmendinger, Luca
AU - Kluth, Martina
AU - Chirico, Victoria
AU - Luebke, Andreas M
AU - Höflmayer, Doris
AU - Hinsch, Andrea
AU - Jacobsen, Frank
AU - Hube-Magg, Claudia
AU - Möller-Koop, Christina
AU - Dahlem, Roland
AU - Fisch, Margit
AU - Rink, Michael
AU - Riechardt, Silke
AU - Tsourlakis, Maria Christina
AU - Büscheck, Franziska
AU - Bernreuther, Christian
AU - Clauditz, Till
AU - Lebok, Patrick
AU - Simon, Ronald
AU - Sauter, Guido
AU - Wilczak, Waldemar
AU - Fraune, Christoph
N1 - Copyright © 2020 Elsevier Inc. All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - BACKGROUND: The ongoing approval of adjuvant systemic therapy in high-risk kidney tumor will increase the demand for prognostic assessment in these tumors. 9p21 deletion has been suggested as a possible prognostic feature in clear cell kidney cancer.MATERIAL AND METHODS: To learn more on the prognostic relevance of 9p21 deletions in clear cell and other kidney tumors, 1,809 kidney tumor specimens were analyzed by dual-labeling fluorescence in situ hybridization (FISH) with probes for 9p21 and centromere 9 in a tissue microarray format. Results were compared to histologic tumor type, pT stage, grade, and patient outcome.RESULTS: A total of 1,341 (74%) of tumor samples had interpretable FISH results. 9p21 deletion was found in 4.4% of 894 clear cell, 5.1% of 197 papillary, and 4.2% of 71 chromophobe carcinomas. 9p21 deletions were not found in 112 oncocytomas and in 21 clear cell tubulo-papillary cancers. In clear cell carcinomas, 9p deletions were associated with advanced stage (P = 0.009) and nodal metastasis (P = 0.0067), but not with ISUP grade (P = 0.1039) and distant metastasis (P = 0.4809). Also, in papillary carcinomas, 9p deletions were associated with advanced stage (P = 0.0008) and nodal metastasis (P = 0.0202) but not with ISUP grade (0.0904) and distant metastasis (P = 0.2022). Follow-up data were available for 789 clear cell and 177 papillary cancers. In both tumor entities, 9p21 deletions were associated with shortened overall survival, tumor-specific death, and progression-free survival in univariate analysis (P < 0.02 each). In a multivariate analysis, 9p21 deletion was an independent predictor of early tumor recurrence (P = 0.04).CONCLUSION: 9p21 deletions, 9p21 deletions identify a small subset of aggressive renal carcinomas. 9p deletion assessment may be clinically useful to identify high-risk renal cell carcinomas.
AB - BACKGROUND: The ongoing approval of adjuvant systemic therapy in high-risk kidney tumor will increase the demand for prognostic assessment in these tumors. 9p21 deletion has been suggested as a possible prognostic feature in clear cell kidney cancer.MATERIAL AND METHODS: To learn more on the prognostic relevance of 9p21 deletions in clear cell and other kidney tumors, 1,809 kidney tumor specimens were analyzed by dual-labeling fluorescence in situ hybridization (FISH) with probes for 9p21 and centromere 9 in a tissue microarray format. Results were compared to histologic tumor type, pT stage, grade, and patient outcome.RESULTS: A total of 1,341 (74%) of tumor samples had interpretable FISH results. 9p21 deletion was found in 4.4% of 894 clear cell, 5.1% of 197 papillary, and 4.2% of 71 chromophobe carcinomas. 9p21 deletions were not found in 112 oncocytomas and in 21 clear cell tubulo-papillary cancers. In clear cell carcinomas, 9p deletions were associated with advanced stage (P = 0.009) and nodal metastasis (P = 0.0067), but not with ISUP grade (P = 0.1039) and distant metastasis (P = 0.4809). Also, in papillary carcinomas, 9p deletions were associated with advanced stage (P = 0.0008) and nodal metastasis (P = 0.0202) but not with ISUP grade (0.0904) and distant metastasis (P = 0.2022). Follow-up data were available for 789 clear cell and 177 papillary cancers. In both tumor entities, 9p21 deletions were associated with shortened overall survival, tumor-specific death, and progression-free survival in univariate analysis (P < 0.02 each). In a multivariate analysis, 9p21 deletion was an independent predictor of early tumor recurrence (P = 0.04).CONCLUSION: 9p21 deletions, 9p21 deletions identify a small subset of aggressive renal carcinomas. 9p deletion assessment may be clinically useful to identify high-risk renal cell carcinomas.
U2 - 10.1016/j.urolonc.2020.02.022
DO - 10.1016/j.urolonc.2020.02.022
M3 - SCORING: Journal article
C2 - 32241691
VL - 38
SP - 605.e1-605.e8
JO - UROL ONCOL-SEMIN ORI
JF - UROL ONCOL-SEMIN ORI
SN - 1078-1439
IS - 6
ER -
